Vaccinex raises ~$650K in private placement of 3.14M shares at $0.207/share

VACCINEX, INC.

Issued 3,140,095 shares to accredited investors at $0.207 per share for gross proceeds of approximately $650,000.
Shares sold in unregistered transaction under Section 4(a)(2) and Rule 506 of Regulation D.
Company to use net proceeds for pepinemab development, working capital, and general corporate purposes.
Registration rights agreement requires company to file resale registration statement within 120 days of closing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

VACCINEX, INC. entered into Stock Purchase Agreement with the investors named therein valued at aggregate gross proceeds of approximately $650,000 (effective 2023-08-18).

Action: entry
Agreement: equity purchase
Counterparty: the investors named therein
Value: aggregate gross proceeds of approximately $650,000
Effective: 2023-08-18

Exact text from the filing

On August 18, 2023, Vaccinex, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) pursuant to which the Company agreed to issue and sell to the investors named therein (the “Investors”) an aggregate of 3,140,095 shares of common stock, par value $0.0001 per share, of the Company (the “Shares”), at a purchase price of $0.207 per Share (the “Private Placement”).

View on SEC.gov

Browse all material agreements →

VACCINEX, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-218037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.